SCHEMBL17877705

SCHEMBL17877705

N#Cc1cnn(-c2ccc(OC=O)cc2)c1N

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.61
KDM4E B2RXH2 1/20 0.61
MEN1 O00255 1/20 0.61
XDH P47989 2/20 0.59
F2 P00734 1/20 0.42
PTGS2 P35354 4/20 0.41
PTGS1 P23219 3/20 0.41
NPBWR1 P48145 1/20 0.40
MCHR1 Q99705 1/20 0.40
MAPK14 Q16539 2/20 0.38
ALDH1A1 P00352 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
GLA P06280 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
LMNA P02545 1/20 0.37
TSHR P16473 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3300932 0.81 KMT2A (0.66) KMT2AKDM4EMEN1XDHF2
SCHEMBL3871978 0.79 KMT2A (0.62) KMT2AKDM4EMEN1XDHNPBWR1
SCHEMBL3876365 0.77 KMT2A (0.73) KMT2AKDM4EMEN1XDHPTGS2
SCHEMBL1143771 0.76 KMT2A (0.71) KMT2AKDM4EMEN1XDHPTGS2
SCHEMBL1456317 0.76 KMT2A (0.71) KMT2AKDM4EMEN1XDHPTGS2
SCHEMBL4700651 0.76 KMT2A (0.71) KMT2AKDM4EMEN1XDHPTGS2
SCHEMBL3871259 0.76 KMT2A (1.00) KMT2AKDM4EMEN1XDHPTGS2
SCHEMBL60939 0.76 KMT2A (0.71) KMT2AKDM4EMEN1XDHMAPK14
SCHEMBL13430464 0.74 XDH (1.00) KMT2AKDM4EMEN1XDHF2
SCHEMBL6071143 0.74 KMT2A (0.69) KMT2AKDM4EMEN1XDHF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9902728-B2 Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors FORMA THERAPEUTICS, INC. (US) 2018-02-27 US disclosed
US-20160185785-A1 PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS VALO HEALTH, INC. 2016-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160185785-A1 PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS USP7, UBA7, UBXN1 KMT2A 2158/4885KDM4E 994/4885MEN1 1492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.